Financial Performance - The company's operating revenue for 2024 reached ¥882,573,320.58, representing a 5.16% increase compared to ¥839,259,534.36 in 2023[16]. - Net profit attributable to shareholders decreased by 26.07% to ¥119,424,741.26 in 2024 from ¥161,535,015.82 in 2023[16]. - The basic earnings per share fell by 26.09% to ¥0.51 in 2024, down from ¥0.69 in 2023[16]. - The total assets at the end of 2024 were ¥1,559,730,388.14, a 1.10% increase from ¥1,542,710,563.50 at the end of 2023[16]. - The company reported a net cash flow from operating activities of ¥118,332,669.23 in 2024, a decrease of 10.56% from ¥132,298,332.70 in 2023[16]. - The weighted average return on equity decreased to 13.67% in 2024 from 20.53% in 2023, a decline of 6.86%[16]. - The company has seen a decline in net profit after deducting non-recurring gains and losses, with a decrease of 26.45% to ¥101,157,550.11 in 2024 from ¥137,540,602.85 in 2023[16]. - The company reported a negative net profit in the fourth quarter of 2024, amounting to -¥3,001,117.77, indicating challenges in maintaining profitability[18]. Dividend Policy - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the dividend record date, excluding 1.8255 million shares in the repurchase account[4]. - The company has not issued any bonus shares during the profit distribution plan, indicating a focus on cash dividends instead[4]. - The 2023 profit distribution plan was approved, with a cash dividend of 2.5 RMB per 10 shares, totaling 58.1537 million RMB distributed[147]. - For the 2024 profit distribution plan, a cash dividend of 3.0 RMB per 10 shares is proposed, with a total cash dividend amounting to approximately 69.79 million RMB[150]. Industry Position and Market Trends - The company is positioned in the pharmaceutical manufacturing industry, focusing on the pharmaceutical excipients sector, which is experiencing significant transformation and development[25]. - The government has increased support for the biopharmaceutical industry, emphasizing the development of innovative drugs and medical devices, which is expected to enhance market opportunities[26]. - The domestic pharmaceutical manufacturing industry achieved a revenue of CNY 25,298.5 billion in 2024, remaining flat year-on-year, which is below the overall industrial growth rate of +2.1%[27]. - The pharmaceutical manufacturing industry saw a profit of CNY 3,420.7 billion in 2024, representing a year-on-year decline of 1.1%[27]. - The market for pharmaceutical excipients is expected to grow significantly, driven by policies encouraging the development of high-end excipients and new adjuvants for vaccines[27]. Product Development and Innovation - The company has developed 50 products that have obtained drug excipient registration numbers from the CDE, indicating a strong product pipeline[30]. - The company focuses on optimizing product quality and expanding its product line, with a commitment to innovation based on market demand[30]. - The company has accelerated the research and industrialization of new fields such as injectable excipients and premix excipients[36]. - The company aims to complete 3-4 new product CDE registrations and increase R&D investment to meet market demand and improve product performance[96]. Research and Development - The company has invested in a new pharmaceutical excipient production base to expand capacity and strengthen its leading position in the industry[43]. - The R&D budget has been increased by 25% to support the development of innovative technologies and products[130]. - The number of R&D personnel increased by 8.13% to 173 in 2024, compared to 160 in 2023[61]. - Research and development expenses for 2024 were ¥40,952,648.76, a decrease of 2.38% compared to ¥41,952,772.69 in 2023[60]. Corporate Governance - The company has a complete and effective internal control system that spans all levels and aspects of its operations, continuously improving governance standards[112]. - The board of directors consists of 7 members, including 3 independent directors, which exceeds one-third of the total number of directors, complying with legal and regulatory requirements[109]. - The company maintains complete independence in business, personnel, assets, institutions, and finance from its controlling shareholder, ensuring no reliance on or unfair transactions with the controlling shareholder[113]. - The company has established a transparent investor relations management system, ensuring timely and accurate information disclosure to all shareholders[111]. Environmental Responsibility - The company holds valid pollution discharge permits from the Huainan Ecological Environment Bureau, expiring on May 12, 2028, and May 28, 2028[158]. - The company reported a total hazardous waste discharge of 2.58 tons, with no exceedances of discharge standards[159]. - The company has implemented strict environmental protection measures in accordance with relevant regulations and standards[158]. - The company has invested over 6 million yuan in environmental protection facilities and operations during the reporting period[164]. Risk Management - The company has outlined potential risks in its future development outlook, urging investors to pay attention to these risks[4]. - The company faces risks from fluctuations in raw material prices, particularly for key ingredients like wood pulp and refined cotton, which could impact profit margins if costs cannot be passed on to customers[97]. - The company emphasizes quality control throughout the production process to mitigate risks associated with operational errors and raw material quality[99]. Market Strategy - The marketing strategy will focus on "innovation industry, create market," expanding overseas markets and enhancing product recognition and market influence[93]. - The company is actively pursuing opportunities in the health food and plant capsule markets, as well as innovations in traditional Chinese medicine[93]. - The company plans to enhance its market presence and enhance product offerings through new technology development and strategic acquisitions[122]. Employee Management - The total number of employees at the end of the reporting period is 1,065, with 855 from the parent company and 209 from major subsidiaries[143]. - Annual training plans are developed by each department based on needs assessment and past training feedback, approved by the human resources department[146]. - The company maintains a salary policy that aligns with job value and differentiates based on technical and professional capabilities[145]. Shareholder Engagement - The annual shareholders' meeting had a participation rate of 43.24% on May 16, 2024[117]. - The first interim shareholders' meeting in 2024 had a participation rate of 31.56% on August 1, 2024[117]. - The second interim shareholders' meeting in 2024 had a participation rate of 28.16% on August 19, 2024[118]. - The third interim shareholders' meeting in 2024 had a participation rate of 28.85% on November 8, 2024[118].

"聪明钱"流向曝光！暗盘资金破解主力操盘密码>> 化学制药板块短线拉升，罗欣药业（002793）、立方制药（003020）涨停,山河药辅（300452）涨超 10%，美诺华（603538）、森萱医药、天宇股份（300702）、昂利康（002940）、海翔药业（002099） 等跟涨。 ...

安徽山河药用辅料股份有限公司 简式权益变动报告书 上市公司名称：安徽山河药用辅料股份有限公司 股票上市地点：深圳证券交易所 股票简称：山河药辅 股票代码：300452 信息披露义务人名称：上海复星医药产业发展有限公司 住所：浦东新区康桥镇康士路25号350室（康桥） 通讯地址：上海市宜山路1289号A楼 股份变动性质：股份减少 签署日期：2025年4月3日 1 信息披露义务人声明 本部分所述词语或简称于本报告书"释义"所述词语或简称具有相同含义。 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式与准则第15号 ——权益变动报告书》及其他相关法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发行证券 的公司信息披露内容与格式与准则第15号——权益变动报告书》的规定，本报告书已全 面披露了信息披露义务人在安徽山河药用辅料股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通过 ...

安徽山河药用辅料股份有限公司 关于 2025 年第一季度可转债转股情况的公告 证券代码：300452 证券简称：山河药辅 公告编号：2025-011 债券代码：123199 债券简称：山河转债 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、"山河转债"（债券代码：123199）的转股期限为 2023 年 12 月 18 日起至 2029 年 6 月 11 日；最新的转股价格为人民币 13.60 元/股； （一）可转换公司债券发行情况 根据中国证券监督管理委员会《关于同意安徽山河药用辅料股份 有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可 〔2023〕268 号），公司于 2023 年 6 月 12 日向不特定对象发行可转 换公司债券（以下简称"可转债"）3,200,000 张，每张面值人民币 100 元，发行总额 32,000.00 万元。 （二）可转换公司债券上市情况 经深交所同意，公司 32,000.00 万元可转换公司债券已于 2023 年 7 月 7 日起在深交所挂牌交易，债券简称"山河转债"，债券代码 "123199"。 （三）可转 ...

Group 1 - The core viewpoint of the news is the groundbreaking ceremony for the R&D center and production base of Shanhe Pharmaceutical Excipients, which will enhance the company's R&D capabilities and optimize its product structure, contributing to its strategic layout in the high-end pharmaceutical excipients market [1] - The project covers an area of 13,061 square meters with a construction area of 37,500 square meters and a construction period of 2 years, aiming to add an annual production capacity of 1,000 tons of composite excipients [1] - The company is currently a leader in the domestic solid dosage pharmaceutical excipients industry, with increasing market share in health products and plant capsules, and is accelerating the R&D and industrialization of new fields such as injectable excipients and premixed excipients [2] Group 2 - Several products, including microcrystalline cellulose, magnesium stearate, sodium carboxymethyl starch, hydroxypropyl methylcellulose, and cross-linked sodium carboxymethyl cellulose, have leading production and sales levels in China, with multiple products recognized as high-tech products in Anhui Province [2] - The company has developed 48 products that have obtained drug excipient registration numbers from the CDE, and has received food production licenses for several products, making it one of the domestic pharmaceutical excipients manufacturers with a wide range of specialized and series products [3]

证券代码：300452 证券简称：山河药辅 公告编号：2025-010 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于使用部分暂时闲置募集资金购买的理财产品到期赎回 及继续购买理财产品的进展公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）2024 年 4 月 24 日召开第五届董事会第二十二次会议和第五届监事会第二十次 会议，审议通过了《关于使用部分闲置募集资金进行现金管理和部分 闲置自有资金进行委托理财的议案》，2024 年 5 月 16 日召开公司 2023 年度股东大会审议通过上述议案。在不影响募集资金投资项目正常进 行及公司正常生产经营并确保资金安全的前提下，公司及子公司拟使 用额度不超过人民币 1.2 亿元（含本数）的闲置募集资金进行现金管 理。在上述额度内，资金可以滚动使用，使用期限自公司股东大会审 议通过之日起 12 个月内有效。公司监事会、独立董事、保荐机构对 该事项已发表明确同意意见。 近日，公司前次使用暂时闲置募集资金购买的理财产品已有部分 到期赎回，公司继续使用暂时闲 ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-009 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于 5%以上股东减持股份计划的预披露公告 公司 5%以上股东上海复星医药产业发展有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的 信息一致。 特别提示： 持安徽山河药用辅料股份有限公司（以下简称"公司"或"本公 司"）股份 23,928,059 股（占公司总股本比例 10.20%）的股东上 海复星医药产业发展有限公司（以下简称"复星医药"）因经营需要， 拟自公告发布之日起 15 个交易日后 90 日内（2025 年 3 月 18 日至 2025 年 6 月 15 日）以集中竞价交易方式和大宗交易方式合计减持 本公司股份不超过 6,978,000 股，即不超过公司总股本（扣除公司回 购股份 1,825,500 股，下同）的 3%。其中，在任意连续 90 日内通过 大宗交易方式减持公司股份的总数，合计不超过公司总股本的 2% （4,652,000 股）；任意连续 90 ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-008 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于使用部分暂时闲置募集资金购买的理财产品到期赎回 及继续购买理财产品的进展公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）2024 年 4 月 24 日召开第五届董事会第二十二次会议和第五届监事会第二十次 会议，审议通过了《关于使用部分闲置募集资金进行现金管理和部分 闲置自有资金进行委托理财的议案》，2024 年 5 月 16 日召开公司 2023 年度股东大会审议通过上述议案。在不影响募集资金投资项目正常进 行及公司正常生产经营并确保资金安全的前提下，公司及子公司拟使 用额度不超过人民币 1.2 亿元（含本数）的闲置募集资金进行现金管 理。在上述额度内，资金可以滚动使用，使用期限自公司股东大会审 议通过之日起 12 个月内有效。公司监事会、独立董事、保荐机构对 该事项已发表明确同意意见。 近日，公司前次使用暂时闲置募集资金购买的理财产品已有部分 到期赎回，公司继续使用暂时闲 ...

安徽山河药用辅料股份有限公司 证券代码：300452 证券简称：山河药辅 公告编号：2025-005 债券代码：123199 债券简称：山河转债 关于完成股份回购暨回购实施结果的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）于 2024 年 1 月 9 日召开第六届董事会第四次会议，审议通过了《关于完成回 购公司股份的议案》，公司决定完成回购公司股份，现将相关情况公 告如下： 一、回购公司股份的基本情况 公司于 2024 年 2 月 7 日召开第五届董事会第二十一次会议、 第五届监事会第十九次会议，审议通过了《关于公司回购股份方案的 议案》，同意公司使用自有资金以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激 励。本次回购股份的资金总额不低于人民币 2,000 万元（含）且不 超过人民币 3,200 万元（含），回购价格不超过人民币 18.00 元/ 股（含）。具体回购股份的数量以公司实际回购的股份数量为准。本 次回购股份的实施期限为自董事会审议通过本次回购股份方案之日 起 ...

本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 一、审议通过《关于使用部分募集资金和自有资金向全资子公司增 资以实施募投项目的议案》 同意使用部分募集资金和自有资金向全资子公司合肥山河医药科技 有限公司（以下简称"合肥山河"）增资 9200 万元用于实施"合肥研发中 心及生产基地项目"，其中募集资金 6000 万元、自有资金 3200 万元。 证券代码：300452 证券简称：山河药辅 公告编号：2025-006 债券代码：123199 债券简称：山河转债 董事会认为：公司本次使用部分募集资金和自有资金向全资子公司增 资以实施募投项目的事项，符合公司实际经营需要，符合募集资金使用计 划，不存在变相改变募集资金投向的情况，不存在影响募投项目正常进行 安徽山河药用辅料股份有限公司 第六届董事会第四次会议决议公告 安徽山河药用辅料股份有限公司（以下简称"公司"）第六届董事会 第四次会议于 2025 年 1 月 9 日上午在公司三楼会议室召开，应出席会议 董事 7 人，实际出席会议董事 7 人。公司第六届董事会第四次会议通知已 于2024年1月6日以电子邮件、传真及电话通知的方式向 ...